ZCM
VIR icon

Ziegler Capital Management’s Vir Biotechnology VIR Stock Holding History

Ziegler Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-24,672
Closed -$605K – 413
2023
Q2 		$605K Buy
24,672
+1,520
+7% +$38.2K 0.02% 334
2023
Q1 		$539K Buy
+23,152
New +$592K 0.02% 345

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ziegler Capital Management's VIR Position: Q3 2023 in Review

Ziegler Capital Management sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 24,672 shares — an estimated $605K sold.

Ziegler Capital Management first reported a position in VIR in Q1 2023 and held it in 2 quarters. The position peaked at $605K in Q2 2023. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • Ziegler Capital Management reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Ziegler Capital Management sold 24,672 Vir Biotechnology shares in Q3 2023, an estimated $605K.
  • Ziegler Capital Management first reported a position in Vir Biotechnology in Q1 2023 and held it in 2 quarters.
  • Ziegler Capital Management's Vir Biotechnology position peaked at $605K in Q2 2023.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Ziegler Capital Management's 13F filing for Q3 2023, filed 16 Oct 2023.